Evidence map›Paper›PMID 39763374›Full record

ArticleHuman vaccines & immunotherapeutics2025

The novel CD16A/anti-CD3 bifunctional protein, eCD16A/anti-CD3-BFP, redirects T cell cytotoxicity toward antibody-bound target cells.

Chien-Ting Lin, Shang-Ju Wu, Cheng Hao Liao, Reyhung Roc Weng, Chun-Ming Lin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chien-Ting LinDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Shang-Ju WuDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Cheng Hao LiaoDepartment of Research and Development, ManySmart Therapeutics, Taipei, Taiwan.
Reyhung Roc WengDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Chun-Ming LinDepartment of Research and Development, ManySmart Therapeutics, Taipei, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal antibodies enhance innate immunity, while bispecific T cell engager antibodies redirect adaptive T cell immunity. To stimulate both innate and adaptive mechanisms, we created a bifunctional eCD16A/anti-CD3-BFP adapter protein for combined use with clinically approved monoclonal IgG1 antibodies. The adaptor protein contains the extracellular domain of the human CD16A high-affinity variant, which binds the Fc domain of IgG1 antibodies, and an anti-human CD3 single-chain variable fragment that redirects T cell cytotoxicity. Functional characterization of eCD16A/anti-CD3-BFP was performed using

Indexed as

Antibodies, BispecificCD3 ComplexReceptors, IgGAnimalsCell Line, TumorFemaleHumansMiceNeoplasmsRituximabT-Lymphocytes, CytotoxicXenograft Model Antitumor AssaysAntibodies, BispecificCD3 ComplexFCGR3A protein, humanReceptors, IgGRituximabanti-CD3Bifunctional proteinbispecific antibodyCD16lymphoma

Identifiers

PMID39763374
PMCPMC12934127

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.